Logotype for Oric Pharmaceuticals Inc

Oric Pharmaceuticals (ORIC) investor relations material

Oric Pharmaceuticals Baird Global Healthcare Conference 2025 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Oric Pharmaceuticals Inc
Baird Global Healthcare Conference 2025 summary10 Sep, 2025

Pipeline and program updates

  • Lead programs focus on small molecule drug development for solid tumors, specifically prostate and lung cancer, with both in dose optimization and aiming for phase 3 starts next year.

  • ORIC-944, a PRC2 inhibitor for prostate cancer, shows improved drug properties and a differentiated safety profile compared to competitors, with a 20-hour half-life supporting once-daily dosing.

  • Early data for ORIC-944 in combination with AR inhibitors show higher PSA response rates and less severe toxicity than Pfizer's Mezigdomide.

  • ORIC-114 targets multiple lung cancer mutations and is differentiated by safety, tolerability, and CNS activity, with substantial data readouts expected in the next year.

  • Both programs are well-funded, with cash runway extending beyond phase 3 data readouts.

Clinical development and milestones

  • Dose optimization for ORIC-944 is ongoing, with pivotal phase 3 study in CRPC planned for the first half of next year.

  • Incremental data updates for ORIC-944 are expected in the second half of this year, with a major update in Q1 2026 including early durability data.

  • Phase 3 trial design will mirror successful competitor studies, focusing on radiographic PFS as the primary endpoint and enrolling 600–800 patients.

  • For ORIC-114, three lung cancer cohorts will read out in the second half of this year, with additional first-line data and a pivotal study planned for next year.

  • A supply agreement with J&J enables a differentiated combination trial for ORIC-114 and imivantamab, with early data expected mid-2026.

Competitive positioning and market opportunity

  • ORIC-944 is positioned to follow Pfizer’s Mezigdomide by 18–24 months, targeting a large prostate cancer market with potential for 35–40% market share as a second entrant.

  • Differentiation is expected through improved efficacy and safety profiles, especially in toxicity and CNS activity for lung cancer.

  • The company is prepared to independently execute phase 3 studies, with flexibility in AR inhibitor selection based on safety and supply agreements.

  • Strategic interest in both prostate and lung cancer programs is high, with potential for expansion into additional indications.

  • Multiple data milestones and pivotal trial initiations are set for the next 6–12 months, supporting investor attention.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Oric Pharmaceuticals earnings date

Logotype for Oric Pharmaceuticals Inc
Q3 202511 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Oric Pharmaceuticals earnings date

Logotype for Oric Pharmaceuticals Inc
Q3 202511 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Oric Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies aimed at overcoming resistance in cancer. The company is dedicated to addressing one of the most significant challenges in oncology by targeting resistance mechanisms to improve the efficacy and durability of cancer treatments. Oric's research is concentrated on three primary resistance pathways: innate resistance, acquired resistance, and bypass resistance. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage